In particular, in PTC patients, coexisting BRAF V600E and TERT promoter mutations are associated with increased cancer aggressiveness, lymph node and distant metastases, and an advanced stage and increase tumor recurrence and mortality more rapidly than either alone [32,33,34]. Here, TERT is linked to neoplasm.